Avalo Therapeutics's total assets for Q2 2025 were $126.58M, a decrease of -8.62% from the previous quarter. AVTX total liabilities were $22.01M for the fiscal quarter, a 38.35% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.